$VIGONVITA-B(02630.HK) rose by 20%. The oral nucleotide drug VV116 has been confirmed to have significant antiviral activity against the Nipah virus. Coupled with the prior approval from the National Medical Products Administration for Phase III clinical trials, the potential of the antiviral pipeline has been unlocked.
As an unprofitable innovative drug listed only at the end of last year, its valuation relies heavily on pipeline milestones. Consequently, it exhibits particularly high elasticity with any positive data. Whether this news-driven surge can continue depends on subsequent clinical progress and indication approvals.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
